BIOMAT Database Logo BIOMAT Database Logo

[Use of cardioselective beta-adrenergic blockaders in supportive treatment of bronchial asthma]. 1972

S Sterkowicz, and S Antczak, and E Antczak

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011292 Premedication Preliminary administration of a drug preceding a diagnostic, therapeutic, or surgical procedure. The commonest types of premedication are antibiotics (ANTIBIOTIC PROPHYLAXIS) and anti-anxiety agents. It does not include PREANESTHETIC MEDICATION. Premedications
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000319 Adrenergic beta-Antagonists Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. Adrenergic beta-Antagonist,Adrenergic beta-Receptor Blockader,Adrenergic beta-Receptor Blockaders,beta-Adrenergic Antagonist,beta-Adrenergic Blocker,beta-Adrenergic Blocking Agent,beta-Adrenergic Blocking Agents,beta-Adrenergic Receptor Blockader,beta-Adrenergic Receptor Blockaders,beta-Adrenoceptor Antagonist,beta-Blockers, Adrenergic,beta-Adrenergic Antagonists,beta-Adrenergic Blockers,beta-Adrenoceptor Antagonists,Adrenergic beta Antagonist,Adrenergic beta Antagonists,Adrenergic beta Receptor Blockader,Adrenergic beta Receptor Blockaders,Adrenergic beta-Blockers,Agent, beta-Adrenergic Blocking,Agents, beta-Adrenergic Blocking,Antagonist, beta-Adrenergic,Antagonist, beta-Adrenoceptor,Antagonists, beta-Adrenergic,Antagonists, beta-Adrenoceptor,Blockader, Adrenergic beta-Receptor,Blockader, beta-Adrenergic Receptor,Blockaders, Adrenergic beta-Receptor,Blockaders, beta-Adrenergic Receptor,Blocker, beta-Adrenergic,Blockers, beta-Adrenergic,Blocking Agent, beta-Adrenergic,Blocking Agents, beta-Adrenergic,Receptor Blockader, beta-Adrenergic,Receptor Blockaders, beta-Adrenergic,beta Adrenergic Antagonist,beta Adrenergic Antagonists,beta Adrenergic Blocker,beta Adrenergic Blockers,beta Adrenergic Blocking Agent,beta Adrenergic Blocking Agents,beta Adrenergic Receptor Blockader,beta Adrenergic Receptor Blockaders,beta Adrenoceptor Antagonist,beta Adrenoceptor Antagonists,beta Blockers, Adrenergic,beta-Antagonist, Adrenergic,beta-Antagonists, Adrenergic,beta-Receptor Blockader, Adrenergic,beta-Receptor Blockaders, Adrenergic
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001249 Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL). Asthma, Bronchial,Bronchial Asthma,Asthmas
D013565 Sympatholytics Drugs that inhibit the actions of the sympathetic nervous system by any mechanism. The most common of these are the ADRENERGIC ANTAGONISTS and drugs that deplete norepinephrine or reduce the release of transmitters from adrenergic postganglionic terminals (see ADRENERGIC AGENTS). Drugs that act in the central nervous system to reduce sympathetic activity (e.g., centrally acting alpha-2 adrenergic agonists, see ADRENERGIC ALPHA-AGONISTS) are included here. Sympathetic-Blocking Agents,Sympatholytic,Sympatholytic Agent,Sympatholytic Drug,Sympatholytic Agents,Sympatholytic Drugs,Sympatholytic Effect,Sympatholytic Effects,Agent, Sympatholytic,Agents, Sympathetic-Blocking,Agents, Sympatholytic,Drug, Sympatholytic,Drugs, Sympatholytic,Effect, Sympatholytic,Effects, Sympatholytic,Sympathetic Blocking Agents

Related Publications

S Sterkowicz, and S Antczak, and E Antczak
[Use of cardioselective beta adrenergic blockaders in the treatment of circulatory failure].
June 1973, Polski tygodnik lekarski (Warsaw, Poland : 1960),
S Sterkowicz, and S Antczak, and E Antczak
[Effect of beta-adrenergic blockaders in bronchial asthma].
December 1971, Medizinische Klinik,
S Sterkowicz, and S Antczak, and E Antczak
[Treatment of bronchial asthma with adrenergic alpha receptor blockaders].
July 1981, Pneumonologia polska,
S Sterkowicz, and S Antczak, and E Antczak
[Adrenergic beta receptor blockaders and bronchial patency].
February 1983, Polskie Archiwum Medycyny Wewnetrznej,
S Sterkowicz, and S Antczak, and E Antczak
[Clinical use of adrenergic beta blockaders].
March 1974, Lille medical : journal de la Faculte de medecine et de pharmacie de l'Universite de Lille,
S Sterkowicz, and S Antczak, and E Antczak
[Use of cardioselective adrenergic beta 1 receptor blockader spesicor in patients with ischemic heart disease associated with bronchial asthma].
July 1987, Klinicheskaia meditsina,
S Sterkowicz, and S Antczak, and E Antczak
[Beta adrenergic blockaders. Their use in cardiology].
February 1972, Arquivos brasileiros de cardiologia,
S Sterkowicz, and S Antczak, and E Antczak
[Use of beta-adrenergic blockaders in the treatment of arterial hypertension].
March 1978, Kardiologiia,
S Sterkowicz, and S Antczak, and E Antczak
[Use of adrenergic beta receptor blockaders in gastroenterology].
January 1988, Klinicheskaia meditsina,
S Sterkowicz, and S Antczak, and E Antczak
Cardioselective beta-adrenergic blockade.
September 1972, Proceedings of the Royal Society of Medicine,
Copied contents to your clipboard!